Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


Articles published in J Immunother

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    August 2020
  1. VAN ZEIJL MCT, Haanen JBAG, Wouters MWJM, de Wreede LC, et al
    Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
    J Immunother. 2020 Aug 14. doi: 10.1097/CJI.0000000000000334.
    PubMed     Abstract available


  2. COMITO F, Leslie I, Boos L, Furness A, et al
    Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.
    J Immunother. 2020 Aug 11. doi: 10.1097/CJI.0000000000000333.
    PubMed     Abstract available


    June 2020
  3. GKOUFA A, Gogas H, Diamantopoulos PT, Ziogas DC, et al
    Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
    J Immunother. 2020 Jun 16. doi: 10.1097/CJI.0000000000000326.
    PubMed     Abstract available


    March 2020
  4. SUNSHINE JC, Sosman J, Shetty A, Choi JN, et al
    Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy.
    J Immunother. 2020 Mar 31. doi: 10.1097/CJI.0000000000000319.
    PubMed     Abstract available


    October 2019
  5. LOGAN IT, Zaman S, Hussein L, Perrett CM, et al
    Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
    J Immunother. 2019 Oct 23. doi: 10.1097/CJI.0000000000000302.
    PubMed     Abstract available


    September 2019
  6. FROHLICH M, Wang H, Sakr L
    Sarcoid-like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma.
    J Immunother. 2019 Sep 24. doi: 10.1097/CJI.0000000000000298.
    PubMed     Abstract available


  7. JAIN V, Venigalla S, Reddy VK, Lukens JN, et al
    Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
    J Immunother. 2019 Sep 6. doi: 10.1097/CJI.0000000000000294.
    PubMed     Abstract available


    July 2019
  8. ZIEMAN D, Frankel AE
    Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    J Immunother. 2019 Jul 16. doi: 10.1097/CJI.0000000000000291.
    PubMed     Abstract available


    June 2019
  9. KHOURY ZH, Hausner PF, Idzik-Starr CL, Frykenberg MRA, et al
    Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    J Immunother. 2019 Jun 14. doi: 10.1097/CJI.0000000000000282.
    PubMed     Abstract available


  10. LESAGE C, Longvert C, Prey S, Maanaoui S, et al
    Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
    J Immunother. 2019;42:175-179.
    PubMed     Abstract available


    May 2019
  11. BISSCHOP C, Wind TT, Blank CU, Koornstra RHT, et al
    Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000271.
    PubMed     Abstract available


  12. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000277.
    PubMed     Abstract available


  13. AFZAL MZ, Sarwar T, Shirai K
    Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000272.
    PubMed     Abstract available


  14. LESAGE C, Longvert C, Prey S, Maanaoui S, et al
    Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
    J Immunother. 2019 May 15. doi: 10.1097/CJI.0000000000000268.
    PubMed     Abstract available


    April 2019
  15. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
    J Immunother. 2019 Apr 10. doi: 10.1097/CJI.0000000000000264.
    PubMed     Abstract available


  16. YUEN C, Reid P, Zhang Z, Soliven B, et al
    Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study.
    J Immunother. 2019;42:94-96.
    PubMed     Abstract available


    March 2019
  17. AFZAL MZ, Shirai K
    Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    J Immunother. 2019 Mar 29. doi: 10.1097/CJI.0000000000000265.
    PubMed     Abstract available


  18. DAVIS EJ, Perez MC, Ayoubi N, Zhao S, et al
    Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
    J Immunother. 2019 Mar 13. doi: 10.1097/CJI.0000000000000258.
    PubMed     Abstract available


    February 2019
  19. DIEM S, Fassler M, Bomze D, Ali OH, et al
    Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.
    J Immunother. 2019 Feb 13. doi: 10.1097/CJI.0000000000000255.
    PubMed     Abstract available


    November 2018
  20. LINDENBERG MA, Retel VP, van den Berg JH, Geukes Foppen MH, et al
    Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.
    J Immunother. 2018;41:413-425.
    PubMed     Abstract available


    July 2018
  21. ZHENG F, Dang J, Zhang H, Xu F, et al
    Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    J Immunother. 2018 Jul 30. doi: 10.1097/CJI.0000000000000242.
    PubMed     Abstract available


    June 2018
  22. DIMITRIOU F, Matter AV, Mangana J, Urosevic-Maiwald M, et al
    Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.
    J Immunother. 2018 Jun 22. doi: 10.1097/CJI.0000000000000236.
    PubMed     Abstract available


  23. ZHAO CY, Hwang SJE, Anforth R, Carlos G, et al
    Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
    J Immunother. 2018 Jun 22. doi: 10.1097/CJI.0000000000000237.
    PubMed     Abstract available


    May 2018
  24. TAVERA RJ, Forget MA, Kim YU, Sakellariou-Thompson D, et al
    Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
    J Immunother. 2018 May 11. doi: 10.1097/CJI.0000000000000230.
    PubMed     Abstract available


    April 2018
  25. MEHTA GU, Malekzadeh P, Shelton T, White DE, et al
    Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    J Immunother. 2018 Apr 18. doi: 10.1097/CJI.0000000000000223.
    PubMed     Abstract available


    February 2018
  26. TANDON P, Bourassa-Blanchette S, Bishay K, Parlow S, et al
    The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    J Immunother. 2018 Feb 2. doi: 10.1097/CJI.0000000000000213.
    PubMed     Abstract available


    January 2018
  27. GORDY JT, Luo K, Francica B, Drake C, et al
    Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3alpha-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
    J Immunother. 2018 Jan 12. doi: 10.1097/CJI.0000000000000212.
    PubMed     Abstract available


  28. ANASTASOPOULOU A, Papaxoinis G, Diamantopoulos P, Christofidou E, et al
    Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    J Immunother. 2018 Jan 5. doi: 10.1097/CJI.0000000000000210.
    PubMed     Abstract available


  29. SUN Y, Lee SK, Oo TH, Rojas-Hernandez CM, et al
    Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
    J Immunother. 2018;41:32-34.
    PubMed     Abstract available


  30. TAJMIR-RIAHI A, Bergmann T, Schmid M, Agaimy A, et al
    Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.
    J Immunother. 2018;41:35-38.
    PubMed     Abstract available


    December 2017
  31. COWEY CL, Liu FX, Black-Shinn J, Stevinson K, et al
    Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    J Immunother. 2017 Dec 15. doi: 10.1097/CJI.0000000000000204.
    PubMed     Abstract available


    September 2017
  32. ZECCHINI JM, Kim S, Yum K, Friedlander P, et al
    Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    J Immunother. 2017 Sep 18. doi: 10.1097/CJI.0000000000000184.
    PubMed     Abstract available


    July 2017
  33. REDDY SB, Possick JD, Kluger HM, Galan A, et al
    Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    J Immunother. 2017 Jul 21. doi: 10.1097/CJI.0000000000000181.
    PubMed     Abstract available


    June 2017
  34. PUSHKAREVSKAYA A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, et al
    Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    J Immunother. 2017 Jun 9. doi: 10.1097/CJI.0000000000000178.
    PubMed     Abstract available


  35. KELLY WU W, Broman KK, Brownie ER, Kauffmann RM, et al
    Ipilimumab-induced Guillain-Barre Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    J Immunother. 2017;40:196-199.
    PubMed     Abstract available


  36. YU G, Moudgil T, Cui Z, Mou Y, et al
    Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    J Immunother. 2017;40:155-163.
    PubMed     Abstract available


    May 2017
  37. DIAMANTOPOULOS PT, Tsatsou K, Benopoulou O, Anastasopoulou A, et al
    Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    J Immunother. 2017 May 11. doi: 10.1097/CJI.0000000000000172.
    PubMed     Abstract available


    February 2017
  38. DAGOGO-JACK I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, et al
    A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    J Immunother. 2017 Feb 17. doi: 10.1097/CJI.0000000000000159.
    PubMed     Abstract available


  39. BRICOUT M, Petre A, Amini-Adle M, Bezza W, et al
    Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
    J Immunother. 2017;40:77-82.
    PubMed     Abstract available


    January 2017
  40. DAY F, Kumar M, Fenton L, Gedye C, et al
    Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    J Immunother. 2017;40:36-38.
    PubMed     Abstract available


    November 2016
  41. BRIGHT R, Coventry BJ, Eardley-Harris N, Briggs N, et al
    Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    J Immunother. 2016.
    PubMed     Abstract available


  42. JOHNSON DB, Pectasides E, Feld E, Ye F, et al
    Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    J Immunother. 2016.
    PubMed     Abstract available


  43. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
    J Immunother. 2016;39:355-366.
    PubMed     Abstract available


  44. TAHTINEN S, Blattner C, Vaha-Koskela M, Saha D, et al
    T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFalpha Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    J Immunother. 2016;39:343-354.
    PubMed     Abstract available


    September 2016
  45. MA Q, Zhou D, DeLyria ES, Wen X, et al
    Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.
    J Immunother. 2016.
    PubMed     Abstract available


  46. DIEM S, Keller F, Ruesch R, Maillard SA, et al
    Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    J Immunother. 2016.
    PubMed     Abstract available


  47. KROPP LM, De Los Santos JF, McKee SB, Conry RM, et al
    Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
    J Immunother. 2016.
    PubMed     Abstract available


    January 2016
  48. PARK TS, Groh EM, Patel K, Kerkar SP, et al
    Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    J Immunother. 2016;39:1-7.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: